Immunome, Morphimmune reverse merge, with ex-Seagen CEO Clay Siegall to lead a year after domestic abuse arrest

Immunome and Morphimmune will come together as one company through a reverse merger, placing Clay Siegall, Ph.D.—who left his role as CEO of Seagen last year after being arrested for domestic abuse—in the chief executive chair.